Another rambling and sophmorish mess. You don't really think that is a coherent piece do you?
Just one note. How is the stock down 40% if the high was $14.40 and we closed today at $10.77? Isn't that an approximately 25% drop. Guess you are taking a little more literary license with the facts. You appear to be allergic to facts. I presume when you were skipping writing classes last year in 3rd grade you also skipped math.
No difference having entered into a significant agreement with one of the top cancer research centers in the world or the Merck deal. Are you a moron? Do you think biotechs particularly early stage ones trade on earnings?
resulted in a 17 cents pop and a 5% drop. Pretty awful reaction to positive news particularly following a 25% correction. Juno popping again. AF and his mindless hordes on the attack. XON even looking solid. This anemic action is troubling. Hopefully Kirk has more positives in the short term.
Sure, this political science major has a better understanding of CAR-T than Merck. Unfortunately, he has a following of robots with a diminished capacity.
Why would anyone have expected a buy out at this stage? Nothing indicated a buy out was forthcoming.
Moreover, there will likely be more deals in near term. Get real.
From where did you pull out your numbers, $7.00-$7.75? Did they just come to you in a dream? Give us a break with that nonsense you have no idea what it is worth and it is a rather odd post for an alleged long.
Not surprising that the only response you can come up with is regarding paragraphs. You appear to have no concept of facts and your writing skills are quite minimal. However, if these blog posts of yours give you a sense of worth I guess that is a good thing.
The blog post appears to have been written by a kid in junior high school. Broken sentences, poor transitions, disjointed arguments and minimal foundation for conclusions. Seeking Alpha appears to have no standards. Particularly troublesome is the argument that the arrangement with MD Anderson does not change the "dynamics". The writer appears to have no understanding of who MD Anderson is and their standing in the cancer research community. The fact ZIOP was selected over all others to work with them is an extraordinary game changer. Anyone who thinks $15-$20 million a year for that relationship is a steep price must be a dult who has no grasp of the technology involved or the significant value to ZIOP. Moreover, the use of a 5 year chart on a developing biotech is simply absurd. Does the writer have any understanding of what drives biotech stocks and their valuations. Notably, the blog fails to mention the likelihood of further partnerships with pharma or big biotech which will add further value and justify a much higher valuation and which have been alluded to by senior managment. Lastly, anyone who characterizes a significant investment by Bill Miller as a "plug" truly has contempt for reality and exposes the writer's motives of driving down the share price to benefit his likely meaningless collection of puts.
Run it down? The stock closed a lousy 16 cents off its high of the day. Looks more like traders taking some profit before the weekend.
Actually if we are going to see bad news it would be more likely to occur once after hours trading closes tonight. News released over the weekend particularly Sunday nights is frequently good.